🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareNovo Nordisk vs Eli Lilly — the GLP-1 market landscape in 2026 Page 5

Novo Nordisk vs Eli Lilly — the GLP-1 market landscape in 2026

anders_CPH Thu, Mar 19, 2026 at 1:00 PM 22 replies 1,194 viewsPage 5 of 5
hannah_MT
New Member
23
89
Feb 2026
Bozeman, MT
Mar 26, 2026 at 10:16 PM#21
dan_philly said:
For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine.

Correct as far as it goes. The part it does not cover is what to do when the honest answer is "not enough data", which is more often than anyone likes.

35 8nick_newbie, DadBodDave, AmyNC_wife and 32 others
Reply Quote Save Share Report
mia_MS2
New Member
8
23
Jun 2026
Ann Arbor, MI
Mar 28, 2026 at 5:08 PM#22
dan_philly said:
For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine.

Saving this. It is the first explanation that did not require me to already understand it. I will report back once I have actually tried it.

36 9FDA_TrackerJim, ricardo_MIA, BrianDallas92 and 33 others
Reply Quote Save Share Report
Dr.LeslieOBGYN
Member
567
2,567
May 2024
Dallas, TX
Mar 30, 2026 at 11:59 AM#23

Adding the clinical framing, because it changes how the question reads. Worth answering the question that was asked rather than the one behind it. The narrow version usually has an answer; the broad version usually does not, and answering the broad one is how a thread stops being useful.

37 10james_edin, FranDenver, Dr.BariatricHTX and 34 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
RunnerRach
Member
467
2,123
Aug 2024
Boston, MA
Apr 1, 2026 at 6:49 AM#24
Dr.LeslieOBGYN said:
Worth answering the question that was asked rather than the one behind it.

This is my experience too, for whatever a second data point is worth.

Last edited: Apr 1, 2026 at 9:49 AM
38 11jennifer_SEA, tyler_CSCS, VanRx_Mike and 35 others
Reply Quote Save Share Report
rick_sfbay
Member
289
1,234
Jan 2025
San Francisco, CA
Apr 3, 2026 at 1:38 AM#25
Dr.LeslieOBGYN said:
Worth answering the question that was asked rather than the one behind it.

Adding the part of the answer the thread has not reached. Take it one variable at a time. Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent argument can untangle them after the fact.

39 12Dr.BariatricHTX, LindaRN_retired, tommy_boulder and 36 others
Reply Quote Save Share Report
1345

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register